{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:32:02Z","timestamp":1703464322183},"reference-count":80,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2000,12,23]],"date-time":"2000-12-23T00:00:00Z","timestamp":977529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":2847,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,12,23]]},"DOI":"10.1046\/j.1365-2257.2000.00332.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:17:16Z","timestamp":1047367036000},"page":"313-323","source":"Crossref","is-referenced-by-count":2,"title":["Haemophilias: advances towards genetic engineering replacement therapy"],"prefix":"10.1111","volume":"22","author":[{"given":"G.","family":"Emilien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Maloteaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Penasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Goodeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Casimir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB1|cit1","first-page":"22","article-title":"Viral safety recombinant factor IX","volume":"35","author":"Adamson","year":"1998","journal-title":"Seminars in Hematology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bp980106m","article-title":"Large-scale processing of recombinant retroviruses for gene therapy","volume":"15","author":"Andreadis","year":"1999","journal-title":"Biotechnological Progress"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/j.1460-2075.1988.tb03134.x","article-title":"Nullisomic deletion of the mcf2 transforming gene in two haemophilia B patients","volume":"7","author":"Anson","year":"1988","journal-title":"EMBO Journal"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","article-title":"Factor VIII gene inversions in severe hemophilia A results of an international consortium study","volume":"86","author":"Antonarakis","year":"1995","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1073\/pnas.87.16.6141","article-title":"Expression of human factor IX in rabbit hepatocytes by retrovirus mediated gene transfer: potential for gene therapy of hemophilia B","volume":"87","author":"Armentano","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1073\/pnas.87.13.5173","article-title":"Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs","volume":"87","author":"Axelrod","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0038-1657535","article-title":"Second generation, B-domain deleted recombinant factor VIII","volume":"78","author":"Berntorp","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB8|cit8","first-page":"584","article-title":"Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies","volume":"82","author":"Castaman","year":"1997","journal-title":"Haematologica"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0037-1614449","article-title":"Evaluation of an adenoviral vector encoding full-length human Factor VIII in hemophiliac mice","volume":"81","author":"Connelly","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/hum.1996.7.2-183","article-title":"High level tissue-specific expression of functional human factor VIII in mice","volume":"7","author":"Connelly","year":"1996","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2516.1998.440380.x","article-title":"Hemophilia A gene therapy","volume":"4","author":"Connelly","year":"1998","journal-title":"Haemophilia"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/hum.1995.6.2-185","article-title":"In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice","volume":"6","author":"Connelly","year":"1995","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/hum.1991.2.1-5","article-title":"Safety issues related to retroviral-mediated gene transfer in humans","volume":"2","author":"Cornetta","year":"1991","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1073\/pnas.89.22.10892","article-title":"Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo","volume":"89","author":"Dai","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1073\/pnas.92.5.1401","article-title":"Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression","volume":"92","author":"Dai","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1073\/pnas.92.4.1023","article-title":"Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice","volume":"92","author":"Dwarki","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1055\/s-0037-1614373","article-title":"The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production","volume":"82","author":"Enjolras","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0038-1655957","article-title":"Recombinant, B. -domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients","volume":"77","author":"Fijnvandraat","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0293-180","article-title":"Towards gene therapy for haemophilia B using primary human keratinocytes","volume":"3","author":"Gerrard","year":"1993","journal-title":"Nature Genetics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/nar\/20.suppl.2027","article-title":"Haemophilia B: Database of Point Mutations and Short Additions and Deletions. 3rd edn","volume":"20","author":"Giannelli","year":"1992","journal-title":"Nucleic Acid Research"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0038-1646370","article-title":"Genetic basis of haemophilia A","volume":"66","author":"Gitschier","year":"1991","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2141.1999.01137.x","article-title":"Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy","volume":"104","author":"Gnatenko","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB24|cit24","first-page":"1111","article-title":"Somatic gene therapy. Present situation and future perspective","volume":"48","author":"Gottschalk","year":"1998","journal-title":"Arzneimittel-Forschung"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V94.7.2263.419k36_2263_2270","article-title":"In vivo marking of Rhesus monkey lymphocytes by adeno-associated viral vectors: Direct comparison with retroviral vectors","volume":"94","author":"Hanazono","year":"1999","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB26|cit26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/4743","article-title":"Long-term correction of canine hemophilia B in gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.V85.9.2447.bloodjournal8592447","article-title":"Expression of the blood clotting factor VIII cDNA is repressed by a transcriptional silencer located in its coding region","volume":"85","author":"Hoeben","year":"1995","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2516.1998.440389.x","article-title":"Hepatic gene therapy for haemophilia B","volume":"4","author":"Kay","year":"1998","journal-title":"Haemophilia"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB29|cit29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression for factor IX in haemophilia B patients treated with AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nature Genetics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1073\/pnas.96.18.9973","article-title":"Gene therapy for the hemophilias","volume":"96","author":"Kay","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"12744","DOI":"10.1073\/pnas.94.24.12744","article-title":"Gene therapy","volume":"94","author":"Kay","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.8211118","article-title":"In vivo gene therapy of hemophilia B. Sustained partial correction in factor IX-deficient dogs","volume":"262","author":"Kay","year":"1993","journal-title":"Science"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB33|cit33","first-page":"466a","article-title":"An immunoisolation device which facilitates cell based prophylactic therapy for hemophilia","volume":"82","author":"Kingdon","year":"1993","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/hum.1995.6.4-469","article-title":"Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation","volume":"6","author":"Koeberl","year":"1995","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-specific integration by adeno-associated virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/(SICI)1097-0290(19990620)63:6<654::AID-BIT3>3.0.CO;2-1","article-title":"Kinetics of retrovirus production and decay","volume":"63","author":"Le Doux","year":"1999","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB37|cit37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/43974","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB38|cit38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/4698","article-title":"Avant-garde gene therapy","volume":"5","author":"Linden","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood.V94.12.3968","article-title":"Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity","volume":"94","author":"Lozier","year":"1999","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/hum.1997.8.12-1481","article-title":"Gut epithelial cells as targets for gene therapy of hemophilia","volume":"8","author":"Lozier","year":"1997","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB41|cit41","first-page":"1342","article-title":"Stage-1 clinical trial of gene therapy for haemophilia B","volume":"36","author":"Lu","year":"1993","journal-title":"Science in China Series B"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2516.1997.00073.x","article-title":"On behalf of UKHCDO Executive committee. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders","volume":"3","author":"Ludlam","year":"1997","journal-title":"Haemophilia"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/hum.1993.4.3-259","article-title":"Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production","volume":"4","author":"Lynch","year":"1993","journal-title":"Human Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders. The First 20 Years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB45|cit45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0169-328x(99)00114-x","article-title":"Neurotensin-SPDP-poly- L-lysine conjugate: a nonviral vector for targeted gene delivery to neural cells","volume":"69","author":"Martinez-Fong","year":"1999","journal-title":"Molecular Brain Research"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.gt.3300548","article-title":"Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia","volume":"5","author":"Monahan","year":"1998","journal-title":"Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1073\/pnas.88.4.1330","article-title":"Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes","volume":"88","author":"Palmer","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood.V73.2.438.438","article-title":"Production of human factor IX in animals by genetically modified skin fibroblasts. potential therapy for hemophilia B","volume":"73","author":"Palmer","year":"1989","journal-title":"Blood"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB50|cit50","first-page":"595","article-title":"Facilitation of retrovirus-mediated gene transfer into hematopoietic stem and progenitor. cells and peripheral blood T-lymphocytes utilizing recombinant fibronectin fragments","volume":"1","author":"Pollok","year":"1999","journal-title":"Current Opinion in Molecular Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/BF00207049","article-title":"Screening for nonsense mutations in patients with severe hemophilia A can provide rapid, direct carrier detection","volume":"89","author":"Reiner","year":"1992","journal-title":"Human Genetics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-7258(98)00020-5","article-title":"Viral vectors for gene therapy","volume":"80","author":"Robbins","year":"1998","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00007611-198905000-00015","article-title":"Wound hematoma: prophylaxis with topical thrombin","volume":"82","author":"Roberts","year":"1989","journal-title":"Southern Medical Journal"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB54|cit54","doi-asserted-by":"crossref","unstructured":"Scharfmann R. Axelrod J.H. Verma I.M. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants Proceedings of the National Academy of Sciences of the USA 88 , 4626 4630","DOI":"10.1073\/pnas.88.11.4626"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJM199012273232604","article-title":"and the Recombinant factor VIII study group Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A","volume":"323","author":"Schwartz","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB56|cit56","first-page":"995","article-title":"Fundamentals and future prospects of gene therapy","volume":"22","author":"Singh","year":"1997","journal-title":"Drugs of the Future"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ng1293-397","article-title":"Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice","volume":"5","author":"Smith","year":"1993","journal-title":"Nature Genetics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB58|cit58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1073\/pnas.85.9.3150","article-title":"An alternative approach to somatic cell gene therapy","volume":"85","author":"St Louis","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1128\/JVI.73.11.9303-9313.1999","article-title":"Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats","volume":"73","author":"Steinwaerder","year":"1999","journal-title":"Journal of Virology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archneur.56.3.287","article-title":"Gene therapy in the central nervous system: The use of recombinant retroviruses","volume":"56","author":"Suhr","year":"1999","journal-title":"Archives of Neurology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB62|cit62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004390050981","article-title":"A. deletion\/insertion leading to the generation of a direct repeat as a result of slipped mispairing and intragenic recombination in the factor VIII gene","volume":"104","author":"Tavassoli","year":"1999","journal-title":"Human Genetics"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.gt.3300715","article-title":"Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors","volume":"5","author":"Themis","year":"1998","journal-title":"Gene Therapy"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-0038-1642651","article-title":"Progress towards gene therapy for the hemophilias","volume":"74","author":"Thompson","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/nar\/19.18.4821","article-title":"Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene","volume":"19","author":"Tuddenham","year":"1991","journal-title":"Nucleic Acids Research"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.1982.tb03888.x","article-title":"Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human hemophilia A and von Willebrand\u2019s disease","volume":"52","author":"Tuddenham","year":"1982","journal-title":"British Journal of Haematology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1093\/nar\/22.22.4851","article-title":"Haemophilia A database of nucleotide substitutions. Deletions, Insertions and Rearrangements of the Factor VIII Gene 2nd edn","volume":"22","author":"Tuddenham","year":"1994","journal-title":"Nucleic Acids Research"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice","volume":"96","author":"Vandendriessche","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1073\/pnas.93.7.3056","article-title":"Successful expression of human factor IX following repeat administration of an adenoviral vector in mice","volume":"93","author":"Walter","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB70|cit70","first-page":"961","article-title":"Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions","volume":"41","author":"Waly","year":"1995","journal-title":"Egyptian Dental Journal"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1073\/pnas.96.7.3906","article-title":"Sustained correction of bleeding disorder in hemophilia B mice by gene therapy","volume":"96","author":"Wang","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0038-1656030","article-title":"A multicenter study of recombinant factor VIII (Recombinate (TM) in previously treated patients with hemophilia A","volume":"77","author":"White","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB73|cit73","unstructured":"White G.C. Levin J. 1987 Disorders of blood coagulation Internal Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"New England Journal of Medicine"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB75|cit75","first-page":"33","article-title":"Clinical evaluation of recombinant factor IX","volume":"35","author":"White","year":"1998","journal-title":"Seminars in Hematology"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1073\/pnas.91.10.4407","article-title":"Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy","volume":"91","author":"Yang","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1021\/bi00335a049","article-title":"Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)","volume":"24","author":"Yoshitake","year":"1985","journal-title":"Biochemistry"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/324380a0","article-title":"Recurrent mutations in haemophilia A give evidence of CpG mutation hot-spots","volume":"324","author":"Youssoufian","year":"1986","journal-title":"Nature"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1073\/pnas.91.11.5148","article-title":"In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery","volume":"91","author":"Zatloukal","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1046\/j.1365-2257.2000.00332.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1126\/science.7687073","article-title":"Systemic gene expression after intravenous DNA delivery into mouse in vivo","volume":"261","author":"Zhu","year":"1993","journal-title":"Science"}],"container-title":["Clinical &amp; Laboratory Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2257.2000.00332.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2257.2000.00332.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1365-2257.2000.00332.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T13:00:37Z","timestamp":1602594037000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1046\/j.1365-2257.2000.00332.x"}},"subtitle":["Haemophilias"],"short-title":[],"issued":{"date-parts":[[2000,12,23]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12,23]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2257.2000.00332.x","archive":["Portico"],"relation":{},"ISSN":["0141-9854"],"issn-type":[{"value":"0141-9854","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12,23]]}}}